Pharmacokinetics of non-targeted mIFNα2 and targeted mIFNα2 in mouse serum after a single 5 mg/kg subcutaneous dose.

In serum targeted mIFNα2 had a terminal half-life of 8.5 hours, Tmax of 0.17 hours, clearance (of fraction absorbed) of 11,343 mL/hr/kg, a volume of distribution (of fraction absorbed) of 138,787 mL/kg and an AUC(0-∞) of 440 hr*ng/mL. non-targeted mIFNα2 had a terminal half-life of 15.0 hours, Tmax of 1 hour, clearance (of fraction absorbed) of 1,611 mL/hr/kg, a volume of distribution (of fraction absorbed) of 34,776 mL/kg and an AUC(0-∞) of 3,104 hr*ng/mL. Using the an AUC(0-∞) calculated here and from those determined in Fig. 1 (see Table 1) it was possible to determine the systemic bioavailability of each molecule. This was determined to be 7.3% for targeted mIFNα2 and 26.6% for non-targeted mIFNα2.Pharmacokinetics of non-targeted mIFNα2 and targeted mIFNα2 in mouse serum after a single 5 mg/kg subcutaneous dose.